Searle Pakistan Limited (SPL) was incorporated in Pakistan as a Private Limited Company on October 5, 1965 as a subsidiary of G.D. Searle & Co., U.S.A. In 1966, Searle Pakistan (Private) Limited acquired a small manufacturing facility in S.I.T.E. and production of Aldactone, Lomotil, Diodoquin, Ovulen, Neomycin Sulphate, Probanthine and Hydryllin, etc. started there. Over the years the operation expanded and during 1984 construction of a new factory started. During mid 1986 manufacturing operations of high quality pharmaceutical products commenced at this newly built factory at Plot # F-319, S.I.T.E. Area, Karachi, measuring 5.24 acres.
On 29th April 1993, G.D. Searle & Company as part of its global policy, disinvested its shares in Pakistan. On November 14, 1993, the company was converted into a Public Limited Company
As a further milestone, during 1996 Ministry of Health, Islamabad, also allowed the manufacturing of Antibiotic products in a dedicated area constructed within SPL present manufacturing facility where production of some excellent antibiotic drugs is being carried out.
During 1996 SPL also joined a limited group of Pharmaceutical Companies, which are allowed to manufacture semi-basic active raw material for pharmaceutical preparations in their manufacturing facilities.
Searle's manufacturing facility conforms to the strictest requirements of GMP and employs systems and procedures of the highest standards to provide manufacturing, quality control, warehousing and physical distribution services to the company, medical profession and ultimate users. The plant is being significantly expanded in all areas to cater for its ever expending manufacturing operations in future.
SPL is one of the leading pharmaceutical companies in Pakistan having two state-of-the art manufacturing facilities in Karachi and Lahore. The manufacturing plants are the most modern in the country. The company has consistently invested heavily in new technologies and state-of-the-art equipment, which has been instrumental in improving plant efficiencies and curtailing manufacturing costs.
SPL has a fully developed and professional marketing operation divided into four separate business lines. The first line which deals with G.D. Searle, Grunenthal - Germany, Forest Laboratories U.K. Limited, 3M - England, Orion Pharma - Finland, Lisapharma - Italy and SPL's own developed products is headed by Director Marketing, Searle Pharma.
The second line deals with products licensed from Sanofi~Aventis, as well as Menarini and SPL's own developed products and is headed by Director Marketing Searle Pharma Division II. The third line deals with Consumer items and is supervised by Group Brand Manager, Consumer Products. Fourth line deals with export business. International Business Division is headed by Senior Manager International Businesss.
Searle enjoys an excellent reputation in the field of pharmaceuticals and health care products throughout the country and is recognized as a dedicated provider of quality healthcare products committed to research and development and its ethical and professional standards.
Searle is one of the largest national pharmaceutical companies of Pakistan. As per 4th quarter 2008 of Pakistan Pharmaceutical Index (IMS) which is regarded as a reference publication by Pharmaceutical Industry, Searle corporate ranking is 11th in the Pakistan Pharmaceuticals market with a market share of 2.4%.
The company employs around 800 permanent staff members including a dedicated sales force who call on doctors, pharmacists, retail outlets and wholesalers to promote the company's products. The hallmark of SPL's success has been the highly motivated and well trained sales and marketing team which is consistently engaged in a wide variety of professional marketing activities including seminars, symposia, round table discussions, film shows and clinical trials.
International Business Division (IBD) of Searle Pakistan is growing at a fast pace. IBD is working on its objectives of establishing Searle products beyond the geographical boundaries of Pakistan. Adding new products to the portfolio, in most of the countries provides an opportunity to build on the base already established in those markets. In order to provide professional services to our customers in each market, number of employees is also increasing. IBD team now comprises of more that 70 men and women from different nationalities based in Vietnam, Myanmar, Bangladesh, Sri Lanka, Afghanistan, Kyrgyzstan, Kazakhstan, Uzbekistan, Turkmenistan, Tajikistan, Azerbaijan, Kenya and Uganda. Representative offices have also been established and Country Business Managers / Sales Managers are based in most of these countries to closely monitor our business activities.
IBD is now entering into a new phase of business. With all its achievements and experiences, IBD team is now geared to grow at an even faster and ready to handle the ever-changing international business scenario.